DE69634204D1 - Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung - Google Patents

Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung

Info

Publication number
DE69634204D1
DE69634204D1 DE69634204T DE69634204T DE69634204D1 DE 69634204 D1 DE69634204 D1 DE 69634204D1 DE 69634204 T DE69634204 T DE 69634204T DE 69634204 T DE69634204 T DE 69634204T DE 69634204 D1 DE69634204 D1 DE 69634204D1
Authority
DE
Germany
Prior art keywords
tablet
formulation
passageway
medicament
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634204T
Other languages
English (en)
Other versions
DE69634204T2 (de
Inventor
Chih-Ming Chen
Der-Yang Lee
Jianbo Xie
Aurelio Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Publication of DE69634204D1 publication Critical patent/DE69634204D1/de
Application granted granted Critical
Publication of DE69634204T2 publication Critical patent/DE69634204T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
DE69634204T 1995-06-07 1996-06-05 Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung Expired - Lifetime DE69634204T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US476455 1983-03-17
US08/476,455 US5654005A (en) 1995-06-07 1995-06-07 Controlled release formulation having a preformed passageway
PCT/US1996/008869 WO1996040080A1 (en) 1995-06-07 1996-06-05 Controlled release formulation having a preformed passageway

Publications (2)

Publication Number Publication Date
DE69634204D1 true DE69634204D1 (de) 2005-02-24
DE69634204T2 DE69634204T2 (de) 2006-01-12

Family

ID=23891918

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634204T Expired - Lifetime DE69634204T2 (de) 1995-06-07 1996-06-05 Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung

Country Status (8)

Country Link
US (1) US5654005A (de)
EP (1) EP0835102B1 (de)
JP (1) JPH11506774A (de)
AT (1) ATE287260T1 (de)
AU (1) AU710110B2 (de)
DE (1) DE69634204T2 (de)
NZ (1) NZ310099A (de)
WO (1) WO1996040080A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
GB9609094D0 (en) * 1996-05-01 1996-07-03 Univ Strathclyde Delivery device
EP0811374A1 (de) 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
ATE314054T1 (de) * 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
DE19729273C2 (de) * 1997-07-09 2000-08-17 Aventis Res & Tech Gmbh & Co Thermoplastische Mischung auf 1,4-alpha-D-Polyglucanbasis, Verfahren zu deren Herstellung und Verwendung
US6270799B1 (en) 1997-09-25 2001-08-07 Bayer Aktiengesellscahft Medicament formulation with a controlled release of an active agent
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
WO2000025757A1 (en) * 1998-10-29 2000-05-11 Merck & Co., Inc. Sustained release delivery of highly water-soluble compounds
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
EP1202747A1 (de) * 1999-07-20 2002-05-08 Merck & Co., Inc. Verabreichungsvorrichtung von wirkstoffdispersionen mit retardierter freisetzung
JP2003520759A (ja) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
EP1712222A3 (de) 1999-12-23 2012-06-20 Pfizer Products Inc. Arzneizusammensetzung mit erhöhter Arzneistoffkonzentration
JP4100910B2 (ja) * 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
CA2395231C (en) 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
IL150568A0 (en) 2000-02-04 2003-02-12 Depomed Inc A controlled release oral drug dosage form
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
EP1411901B1 (de) * 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
CN1596101A (zh) * 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
KR20040081446A (ko) * 2002-01-04 2004-09-21 아이박스 리서치, 인코포레이티드 글리피지드의 서방성을 위한 약물 전달 체계
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
MXPA04012021A (es) * 2002-05-31 2005-08-16 Johnson & Johnson Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
ES2336913T3 (es) * 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US8221792B2 (en) * 2005-07-07 2012-07-17 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en) * 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0702974D0 (en) * 2007-02-15 2007-03-28 Jagotec Ag Method and apparatus for producing a tablet
EP2074993A1 (de) 2007-12-19 2009-07-01 Biovail Laboratories International S.r.l. Venlafaxin enthaltende Filmtabletten mit modifizierter Wirkstofffreisetzung
EP2299983A4 (de) * 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc Stabilisierte atypische antipsychotische formulierung
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
DK2442791T3 (da) 2009-06-16 2020-03-02 Pfizer Former til dosering af apixaban
AU2010300641B2 (en) * 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
JP5638151B2 (ja) 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ 不正加工抵抗性の（ｔａｍｐｅｒｒｅｓｉｓｔａｎｔ）固形経口剤形
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
JP6138798B2 (ja) * 2011-09-16 2017-05-31 パーデュー ファーマ エルピー 不正改変抵抗性即時放出性製剤
JP5922851B2 (ja) 2012-11-30 2016-05-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 活性医薬成分の自己制御放出
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0062321B1 (de) * 1981-04-03 1989-03-01 Fujisawa Pharmaceutical Co., Ltd. Cephalosporinderivate, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Präparate und ihre Ausgangsprodukte
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
ATE72111T1 (de) * 1987-01-14 1992-02-15 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
WO1990008536A1 (en) * 1989-01-30 1990-08-09 Alza Corporation Dosage form for administering calcium antagonist
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
WO1992019209A2 (en) * 1991-04-30 1992-11-12 Fmc Corporation Taste-masked medicaments and their preparation
HU219594B (hu) * 1991-12-27 2001-05-28 Merck And Co. Inc. Szabályozott diszperziós hatóanyag-leadó eszköz és eljárás előállítására

Also Published As

Publication number Publication date
AU710110B2 (en) 1999-09-16
NZ310099A (en) 1999-09-29
EP0835102B1 (de) 2005-01-19
DE69634204T2 (de) 2006-01-12
WO1996040080A1 (en) 1996-12-19
JPH11506774A (ja) 1999-06-15
EP0835102A1 (de) 1998-04-15
ATE287260T1 (de) 2005-02-15
EP0835102A4 (de) 2000-07-19
AU6042796A (en) 1996-12-30
US5654005A (en) 1997-08-05

Similar Documents

Publication Publication Date Title
DE69634204D1 (de) Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung
AU4989997A (en) Soluble form osmotic dose delivery system
DE69636223D1 (de) Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslauföffnung in situ gebildet wird
HK1039054A1 (en) Controlled release tablet comprising a hypoglycemic drug and an antihyperglycemic drug.
ATE251899T1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
MY101593A (en) Sustained release preparation.
GB9025372D0 (en) Pharmaceutical dosage forms
BR0114633A (pt) Formulações farmacêuticas com liberação retardada
WO2004108067A3 (en) Programmed drug delivery system
HK1044480A1 (en) New omeprazole and (s)-omeprazole formulation.
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
FI924419A (fi) Ett osmotiskt doseringssystem foer frigoerande av laekemedel i vaetskeform
MY125548A (en) Water soluble film for oral administration with instant wettability
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
ZA997727B (en) Pharmaceutical composition for application to mucosa.
DE69803940D1 (de) Ophthalmische zusammensetzungen mit verlängerte freisetzung enthaltend im wasser lösliche arzneistoffe
AU2001291526A1 (en) Sustained release composition containing clarithromycin
CA2085871A1 (en) A controlled release drug dispersion delivery device
CA2223014A1 (en) Controlled release formulation having a preformed passageway
WO1997006769A3 (de) Pharmazeutisches präparat mit trypanoziden eigenschaften enthaltend diminazen, pentamidin und phenazon
NZ601969A (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane

Legal Events

Date Code Title Description
8364 No opposition during term of opposition